NAS:IDXX (USA)
Business Description
IDEXX Laboratories Inc
NAICS : 325412
SIC : 2835
One IDEXX Drive, Westbrook, ME, USA, 04092
Compare
Compare
Traded in other countries / regions
IDXX.Austria
•
I1DX34.Brazil
•
IX1.Germany
•
IDXX.Mexico
•
0J8P.UK
•
IDXX.USA
Description
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 3.28 | |||||
| Debt-to-EBITDA | 1.56 | |||||
| Interest Coverage | 28.49 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.92 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.1 | |||||
| 3-Year EBITDA Growth Rate | 22.6 | |||||
| 3-Year EPS without NRI Growth Rate | 26.4 | |||||
| 3-Year FCF Growth Rate | 32.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 8.19 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 12 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.09 | |||||
| 9-Day RSI | 40.11 | |||||
| 14-Day RSI | 46.39 | |||||
| 6-1 Month Momentum % | -27.14 | |||||
| 12-1 Month Momentum % | -45.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.89 | |||||
| Quick Ratio | 0.61 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 74.96 | |||||
| Days Sales Outstanding | 42.86 | |||||
| Days Payable | 29.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.6 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.7 | |||||
| Operating Margin % | 25.77 | |||||
| Net Margin % | 20.07 | |||||
| ROE % | 100.93 | |||||
| ROA % | 26.7 | |||||
| ROIC % | 34.06 | |||||
| ROC (Joel Greenblatt) % | 92.57 | |||||
| ROCE % | 51.73 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 48.27 | |||||
| Forward PE Ratio | 42.53 | |||||
| PE Ratio without NRI | 48.27 | |||||
| Shiller PE Ratio | 82.03 | |||||
| Price-to-Owner-Earnings | 76.06 | |||||
| PEG Ratio | 2.49 | |||||
| PS Ratio | 9.7 | |||||
| PB Ratio | 68.27 | |||||
| Price-to-Tangible-Book | 37401 | |||||
| Price-to-Free-Cash-Flow | 75.03 | |||||
| Price-to-Operating-Cash-Flow | 55.69 | |||||
| EV-to-EBIT | 38.1 | |||||
| EV-to-Forward-EBIT | 34.51 | |||||
| EV-to-EBITDA | 33.77 | |||||
| EV-to-Forward-EBITDA | 30.43 | |||||
| EV-to-Revenue | 9.82 | |||||
| EV-to-Forward-Revenue | 9.54 | |||||
| EV-to-FCF | 77.4 | |||||
| Price-to-Projected-FCF | 5.15 | |||||
| Price-to-DCF (Earnings Based) | 1.27 | |||||
| Price-to-DCF (FCF Based) | 2.23 | |||||
| Price-to-Median-PS-Value | 1.25 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.48 | |||||
| Price-to-Graham-Number | 270.37 | |||||
| Earnings Yield (Greenblatt) % | 2.61 | |||||
| Forward Rate of Return (Yacktman) % | 20.61 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:IDXX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,308.606 | ||
| EPS (TTM) ($) | 7.75 | ||
| Beta | 1.14 | ||
| Volatility % | 40.3 | ||
| 14-Day RSI | 46.39 | ||
| 14-Day ATR ($) | 14.498088 | ||
| 20-Day SMA ($) | 394.5375 | ||
| 12-1 Month Momentum % | -45.2 | ||
| 52-Week Range ($) | 318.5 - 695.18 | ||
| Shares Outstanding (Mil) | 83.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDEXX Laboratories Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||